Study guide

2.2 Official Blueprint and Study Strategy

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

2.2 Official Blueprint and Study Strategy

Key Takeaways Explain This Topic AI

The official CCRA ECO weights are 12%, 18%, 14%, 18%, 25% and 13%.

Clinical Trial Operations and Study/Site Management together account for 43% of the outline.

Average pacing over 180 minutes and 125 items is 86.4 seconds per item.

Last updated: October 2026

Official Blueprint and Study Strategy

Domain Official ECO weight Preparation emphasis

Scientific Concepts and Research Design 12% Protocol, IB, eligibility rationale, design, endpoints and development stages

Ethical and Participant Safety Considerations 18% Consent, participant protection, safety, retention, discontinuation and misconduct

Regulatory Requirements 14% Ethics committee governance, submissions, amendments and regulatory communication

Clinical Trial Operations (GCP) 18% Monitoring plans, responsibilities, feasibility, risk, CAPA, audits and inspections

Study and Site Management Activities 25% Products, samples, equipment, contracts, delegation, visits and essential records

Data Quality 13% Source records, tools, queries, privacy, pharmacovigilance and critical data

The weights sum to 100%. Clinical Trial Operations and Study/Site Management together account for 43% , not half. A study allocation of 100 hours could therefore begin with 12, 18, 14, 18, 25 and 13 hours respectively, then shift time toward demonstrated weaknesses. This is an independent planning example, not ACRP's prescribed study duration.

Map each missed question to a knowledge statement and an applied task. A candidate who knows drug accountability definitions but cannot investigate a missing shipment has a task gap. A candidate who identifies a temperature excursion but assumes a universal storage range has a factual gap. Address the specific gap before repeating a question set.

Strategic Study Framework: The 4-Step Scenario Question Dissection Method

Practise both knowledge and applied scenarios; a question may describe an on-site dilemma requiring a decision within the relevant role. To dissect these scenario questions reliably, adopt a disciplined 4-step framework:

Step 1: Identify the Role and Perspective

Carefully identify whose perspective the question requires. Does the prompt ask: "What is the CRA's most appropriate next action?", "What is the Principal Investigator required to do?", or "What is the Sponsor's primary obligation?" Choosing the right action for the wrong stakeholder is the a common cause of incorrect answers on scenario items.

Step 2: Determine the Trial Milestone and Visit Context

Pinpoint where the scenario takes place in the clinical trial lifecycle:

Pre-Study / Qualification: Focus on site feasibility, facility adequacy, staff qualifications, and patient access.

Initiation: Focus on site staff protocol training, essential document collection, regulatory approvals, and IP receipt.

Interim Monitoring: Focus on ongoing consent verification, ALCOA+ source data verification, safety reporting (SAEs), protocol deviations, and drug accountability.

Close-Out: Focus on final IP reconciliation/destruction, query resolution, trial file reconciliation, and long-term archiving.

Step 3: Stratify the Risk Level

Evaluate the severity of the event described in the vignette:

Immediate Subject Safety Threat: (e.g., patient receiving an incorrect drug dose, active life-threatening toxicity, unapproved consent form). Demands immediate communication with the PI and urgent escalation to the sponsor .

Systemic Non-Compliance / Data Integrity Threat: (e.g., recurrent missing lab results, unauthorized staff performing protocol tests, backdated entries). Demands formal root cause analysis, PI meeting, and a documented CAPA plan .

Routine Administrative Discrepancy: (e.g., typographical error in non-critical visit log, delayed filing of general correspondence). Handled via routine action items and documentation in the monitoring report .

Step 4: Evaluate Answers Against ICH GCP Boundaries

Eliminate options that violate professional monitoring boundaries:

Reject any option where the CRA performs clinical medical decisions or tells an investigator how to practice medicine.

Reject any option where the CRA alters, writes in, or corrects site source documents or eCRFs on behalf of site personnel.

Reject options that propose ignoring an issue, waiting passively for several months, or unilaterally stopping patient treatments without sponsor/PI involvement.

Select the option that demonstrates proactive, documented, collaborative, and protocol-compliant oversight.

Time Management Architecture for the 180-Minute Exam

The CCRA examination allows 180 minutes to complete 125 questions, translating to an average of 86.4 seconds per question . Managing your cognitive pace is essential to prevent fatigue during the final 30 items.

The Two-Pass Strategy

Pass One (Minutes 0 to 135 — ~65 seconds per item): Move steadily through all 125 questions. Answer direct knowledge and definition questions quickly (30–45 seconds). For lengthy scenario vignettes, read the last sentence (the actual question) first to determine what is being asked, then read the scenario stem. If an item is immediately obvious, select the answer and proceed. If you are uncertain between two strong choices, select your best working hypothesis, flag the question for review , and keep moving. Never stall on a single question for more than two minutes.

Pass Two (Minutes 135 to 170 — Reviewing Flagged Items): By minute 135, you should have answered all 125 questions and flagged approximately 15 to 25 challenging items. Use minutes 135–170 for 35 minutes of review, leaving ten minutes for a final check. Use the 35-minute review interval to re-read the flagged stems with fresh eyes, paying close attention to qualifiers like FIRST , BEST , PRIMARY , or IMMEDIATE .

Pass Three (Minutes 170 to 180 — Final Audit): Spend the final 10 minutes confirming that no questions were left unanswered. There is no negative marking or guessing penalty on the CCRA exam. Leaving a question blank guarantees a zero for that item, whereas an educated guess provides at least a 25% to 50% probability of earning the point.

Official sources

Checked October 18, 2026: ACRP CCRA programme , ACRP Initial Certification Handbook, June 2026 , ACRP CCRA Exam Content Outline .